TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Entera Bio ( (ENTX) ) is now available.
Entera Bio announced its third quarter 2025 financial results and business updates, highlighting significant progress in its oral peptide therapies. The company received FDA agreement for its EB613 Phase 3 study, marking a pivotal step in osteoporosis treatment. Phase 2 data showed promising efficacy in younger post-menopausal women, and preclinical data for oral GLP-2 and OXM programs were presented at major conferences. Financially, Entera reported a net loss of $3.2 million for the quarter, with cash reserves expected to support operations into mid-2026.
The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.
Spark’s Take on ENTX Stock
According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.
Entera Bio’s overall stock score reflects a balance between financial challenges and strategic advancements. The company’s financial instability and cash flow issues weigh significantly on the score. However, positive corporate events and strong technical momentum provide some optimism, though valuation remains a concern due to negative earnings.
To see Spark’s full report on ENTX stock, click here.
More about Entera Bio
Entera Bio is a clinical stage company specializing in the development of oral peptide and protein replacement therapies aimed at addressing significant unmet medical needs. The company utilizes a proprietary technology platform, N-Tab™, to develop first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2. Its leading product candidate, EB613, is being developed as the first oral, osteoanabolic tablet treatment for post-menopausal women with osteoporosis.
Average Trading Volume: 152,922
Technical Sentiment Signal: Buy
Current Market Cap: $132.9M
Find detailed analytics on ENTX stock on TipRanks’ Stock Analysis page.